Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Length of hospital stay · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Quality of life  · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Death from all causes (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to lower death from all causes (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Major bleeding · patients with acute pulmonary embolism
Thrombolytic therapy probably leads to higher major haemorrhagic events (duration of compared with heparin: primary outcome measures (moderate certainty).
1 finding from 1 review
Minor haemorrhagic events (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review
Mortality (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in mortality (up to 6 months) compared with anticoagulation (moderate certainty).
1 finding from 1 review
Symtomatic lower extremity venous thrombosis confirmed by Doppler ultrasound or venography (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in symtomatic lower extremity venous thrombosis confirmed by Doppler… compared with anticoagulation (moderate certainty).
1 finding from 1 review
Filter‐related complications (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
1 finding from 1 review
Major bleeding · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa
Retrievable vena caval filters with anticoagulation showed no clear difference in major bleedingc (up to 6 months) compared with anticoagulation (moderate certainty).
1 finding from 1 review
Mortality from any cause (up to 90 days) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review
Lower extremity venous thrombosis confirmed by Doppler ultrasound or venography (at 14 days) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review
Filter‐related complications (up to 232 days) · participants who sustained multiple traumatic injuriesa
1 finding from 1 review